Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 75Neoplasms 15Neoplasm Metastasis 9Advanced Breast Cancer 5Neoplasms by Site 3Breast Diseases 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Patient Compliance 2Ovarian Neoplasms 2Endometrial Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Skin Diseases 1Recurrence 1Quality of Life 1Osteoporosis 1Multiple Endocrine Neoplasia Type 1 1Low Grade Serous Ovarian Cancer 1Lethal Congenital Contracture Syndrome 2 1Joint Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Cancer Metastatic 1Bone Diseases, Metabolic 1Bone Density 1Arthralgia 1Advanced Metastatic Breast Cancer 1

Interventions

zenocutuzumab 2seribantumab 2pembrolizumab 1patritumab 1osimertinib 1exemestane 1cemiplimab 1Vinorelbine 1Vascular Endothelial Growth Factor A 1Trastuzumab 1Paroxetine 1Paclitaxel 1Letrozole 1Itraconazole 1Fulvestrant 1Erlotinib Hydrochloride 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lethal Congenital Contracture Syndrome 2 × Anastrozole × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡